8-22-13 10:11 AM EDT | Email Article
http://media.marketwire.com/attachments/201308/65065_atossalogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1045133&ProfileId=051205&sourceType=1

SEATTLE, WA -- (Marketwired) -- 08/22/13 -- In the news release, "Atossa Genetics and Its Subsidiary the National Reference Laboratory for Breast Health to Exhibit Their Products and Services at Two Upcoming Conferences," issued Wednesday, August 21, 2013 by Atossa Genetics, Inc. (NASDAQ: ATOS), we are advised by the company that the second embedded link of the first paragraph should go to "http://www.survivorsconvention.com/" rather than "http://gaobgyn.com/resources/meeting-events/" as originally issued. Complete corrected text follows.

Atossa Genetics and Its Subsidiary the National Reference Laboratory for Breast Health to Exhibit Their Products and Services at Two Upcoming Conferences

SEATTLE, WA -- August 21, 2013 -- Atossa Genetics Inc. (NASDAQ: ATOS) and its subsidiary The National Reference Laboratory for Breast Health (NRLBH), will display their products and services at the Georgia Obstetrical and Gynecological Society 2013 Annual Meeting, August 22-25, in Greensboro, Georgia, and at the inaugural National Women's Survivors Convention, August 22-24, in Nashville, Tennessee.

The ForeCYTE Breast Health Test, provided by the NRLBH, detects reversible precancerous conditions in the breast up to eight years before they become cancer. The test uses a sample of nipple aspirate fluid collected with Atossa's hand-held, FDA Class II medical device which is quick, painless, and non-invasive and can be administered during an OB/GYN office visit. Unlike mammograms, which are commonly recommended for women starting at age 40 to 50, the ForeCYTE Breast Health Test is more age agnostic, uses no radiation and does not require invasive biopsy needles or surgical incisions. To view a video about Atossa's device, click here: https://vimeo.com/62365818.

"The ForeCYTE Breast Health Test serves as an early warning system for the detection of precancerous cellular abnormalities that heighten a woman's breast cancer risk," said Chris Destro, Vice President of Sales and Marketing. "This is particularly true for younger women for whom little is done today in terms of risk assessment or screening unless there is a specific reason for concern, such as a strong family history. We believe the ForeCYTE Breast Health Test empowers all women with vital information that they and their doctors can use to take charge of their breast health and make more informed treatment decisions."

Mr. Destro continued, "We are excited to work with outstanding organizations like the Women Survivors Alliance, which provide vital services to breast cancer victims. In times of trouble women need to come together, share information and feel the support of other women as they cope with their disease and their new normal. As we continue to roll out the ForeCYTE test nationally, we believe we will have a significant impact on the incidence of this dreaded disease so that in the future fewer women will be afflicted. We look forward to meeting with physicians, patients and other breast health stakeholders at these important conferences."

Atossa's specimen collection devices are available through physicians nationwide.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, the NRLBH, patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information on Atossa, please visit www.atossagenetics.com. For additional information on the ForeCYTE test and the National Reference Laboratory for Breast Health, please visit www.nrlbh.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:

Atossa Genetics, Inc.
Chris Destro
VP, Sales & Marketing
(O) 800-351-3902
Email Contact

MBS Value Partners
Matthew D. Haines
(Investors)
Managing Director
(O) 212-710-9686
Email Contact

JQA Partners
Jules Abraham
(Media)
Principal
(O) 917-885-7378
Email Contact

Add a Comment

News   More...

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Content Partners
Morningstar - - / CORRECTION - Atossa Genetics, Inc.
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Author |  Collection |  Interest |  Popularity

Previous: / CORRECTION - ARC Document Solutions Announces Third Quarter 2013 Results Conference Call  |  Next: / CORRECTION - Brookfield Property Partners Successful in Tender Offer